Gene expression analysis of gallium-resistant and gallium-sensitive lymphoma cells reveals a role for metal-responsive transcription factor-1, metallothionein-2A, and zic transporter-1 in modulating the antineoplastic activity of gallium nitrate

Molecular Cancer Therapeutics

Volumn 6, Issue 2, 2007, Pages 633-643

  Yang, Meiying ^a   Kroft, Steven H ^a   Chitambar, Christopher R ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GALLIUM NITRATE; METAL RESPONSIVE TRANSCRIPTION FACTOR 1; METALLOTHIONEIN II; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ZINC; ZINC TRANSPORTER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL PROTECTION; CONTROLLED STUDY; DNA MICROARRAY; DRUG CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG SENSITIVITY; GENE EXPRESSION; GENE INDUCTION; GENE SEQUENCE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPHOMA CELL; METAL METABOLISM; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; TRANSCRIPTION REGULATION; ZINC METABOLISM;

ANTINEOPLASTIC AGENTS; BLOTTING, NORTHERN; CATION TRANSPORT PROTEINS; CELL PROLIFERATION; DNA, COMPLEMENTARY; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GALLIUM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, LYMPHOCYTIC; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; METALLOTHIONEIN; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 33847409311     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0557     Document Type: Article

References (45)

1. Weick JK, Stephens RL, Baker LH, Jones SE. Gallium nitrate in malignant lymphoma: a Southwest Oncology Group study. Cancer Treat Rep 1983;67:823-5.
2. Warrell RP, Jr., Coonley CJ, Straus DJ, Young CW. Treatment of patients with advanced malignant lymphoma using gallium nitrate administered as a seven-day continuous infusion. Cancer 1983;51: 1982-7.
3. Keller J, Bartolucci A, Carpenter JT, Jr., Feagler J. Phase II evaluation of bolus gallium nitrate in lymphoproliferative disorders: a Southeastern Cancer Study Group trial. Cancer Treat Rep 1986;70:1221-3.
4. Chitambar CR, Zahir SA, Ritch PS, Anderson T. Evaluation of continuous-infusion gallium nitrate and hydroxyurea in combination for the treatment of refractory non-Hodgkin's lymphoma. Am J Clin Oncol 1997;20:173-8.
5. Straus DJ. Gallium nitrate in the treatment of lymphoma. Semin Oncol 2003;30:25-33.
6. Pro B, Bociek RG, Chitambar CR, et al. Phase 2 multicenter trial of gallium nitrate in patients with advanced non-Hodgkin's lymphoma (NHL). Blood 2004;104:682A.
7. Harris WR, Pecoraro VL. Thermodynamic binding constants for gallium transferrin. Biochemistry 1983;22:292-9.
8. Larson SM, Rasey JS, Allen DR, et al. Common pathway for tumor cell uptake of gallium-67 and iron-59 via a transferrin receptor. J Natl Cancer Inst 1980;64:41-53.
9. Chitambar CR, Zivkovic Z. Uptake of gallium-67 by human leukemic cells: demonstration of transferrin receptor-dependent and transferrin-independent mechanisms. Cancer Res 1987;47:3929-34.
10. Habeshaw JA, Lister TA, Stansfeld AG. Correlation of transferrin receptor expression with histological class and outcome in non-Hodgkin lymphoma. Lancet 1983;1:498-501.
11. Esserman L, Takahashi S, Rojas V, Warkne R, Levy R. An epitope of the transferrin receptor is exposed on the cell surface of high-grade lymphoma but not low-grade human lymphomas. Blood 1989;74: 2718-29.
12. Kiratli PO, Canpinar H, Ruacan S, Kansu E. Correlation of flow cytometric parameters and transferrin receptors with gallium-67 scintigraphic images in lymphoma patients. Nucl Med Commun 2000;21:925-31.
13. Chitambar CR, Matthaeus WG, Antholine WE, Graff K, O'Brien WJ. Inhibition of leukemic HL60 cell growth by transferrin-gallium: effects on ribonucleotide reductase and demonstration of drug synergy with hydroxyurea. Blood 1988;72:1930-6.
14. Chitambar CR, Narasimhan J, Guy J, Sam DS, O'Brien WJ. Inhibition of ribonucleotide reductase by gallium in murine leukemic L1210 cells. Cancer Res 1991;51:6199-201.
15. Narasimhan J, Antholine WE, Chitambar CR. Effect of gallium on the tyrosyl radical of the iron-dependent M2 subunit of ribonucleotide reductase. Biochem Pharmacol 1992;44:2403-8.
16. Bernstein LR. Mechanisms of therapeutic activity for gallium. Pharmacol Rev 1998;50:665-82.
17. Collery P, Keppler B, Madoulet C, Desoize B. Gallium in cancer treatment. Crit Rev Oncol Hematol 2002;42:283-96.
18. Chitambar CR, Wereley JP. Resistance to the antitumor agent gallium nitrate in human leukemic cells is associated with decreased gallium/ iron uptake, increased activity of iron regulatory protein-1, and decreased ferritin production. J Biol Chem 1997;272:12151-7.
19. Chitambar CR, Wereley JP. Transferrin receptor-dependent and -independent iron transport in gallium-resistant human lymphoid leukemic cells. Blood 1998;91:4686-93.
20. Klaassen CD, Liu J, Choudhuri S. Metallothionein: an intracellular protein to protect against cadmium toxicity. Annu Rev Pharmacol Toxicol 1999;39:267-94.
21. Davis SR, Cousins RJ. Metallothionein expression in animals: a physiological perspective on function. J Nutr 2000;130:1085-8.
22. Cherian MG, Jayasurya A, Bay BH. Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res 2003;533:201-9.
23. Tucker CA, Bebb G, Klasa RJ, et al. Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of mantle cell lymphoma. Leuk Res 2006;30:449-57.
24. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immmunol Methods 1983;65:55-63.
25. Mididoddi S, McGuirt JP, Sens MA, Todd JH, Sens DA. Isoform-specific expression of metallothionein mRNA in the developing and adult human kidney. Toxicol Lett 1996;85:17-27.
26. Fang Y, Svoboda KK. Nicotine inhibits myofibroblast differentiation in human gingival fibroblasts. J Cell Biochem 2005;95:1108-19.
27. Aoki Y, Tohyama C, Suzuki KT. A Western blotting procedure for detection of metallothionein. J Biochem Biophys Methods 1991;23: 207-16.
28. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
29. Wadman IA, Osada H, Grutz GG, et al. The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1, and Ldb1/NLI proteins. EMBO J 1997; 16:3145-57.
30. Dalton TP, Li Q, Bittel D, Liang L, Andrews GK. Oxidative stress activates metal-responsive transcription factor-1 binding activity. Occupancy in vivo of metal response elements in the metallothionein-1 gene promoter. J Biol Chem 1996;271:26233-41.
31. Radtke F, Heuchel R, Georgiev O, et al. Cloned transcription factor MTF-1 activates the mouse metallothionein 1 promoter. EMBO J 1993;12: 1355-62.
32. Novoa-Takara L, Perkins SL, Qi D, et al. Histogenetic phenotypes of B cells in posttransplant lymphoproliferative disorders by immunohistochemical analysis correlate with transplant type: solid organ vs hematopoietic stem cell transplantation. Am J Clin Pathol 2005;123:104-12.
33. Davies NP, Rahmanto YS, Chitambar CR, Richardson DR. Resistance to the antineoplastic agent gallium nitrate results in marked alterations in intracellular iron and gallium trafficking: identification of novel intermediates. J Pharmacol Exp Ther 2006;317:153-62.
34. Palmiter RD, Findley SO, Whitmore TE, Durnam DM. MT-III, a brain-specific member of the metallothionein gene family. Proc Natl Acad Sci U S A 1992;89:6333-7.
35. McMahon RJ, Cousins RJ. Regulation of the zinc transporter ZnT-1 by dietary zinc Proc Natl Acad Sci U S A 1998;95:4841-6.
36. Palmiter RD, Huang L. Efflux and compartmentalization of zinc by members of the SLC30 family of solute carriers. Pflugers Arch 2004;447: 744-51.
37. Liuzzi JP, Cousins RJ. Mammalian zinc transporters. Annu Rev Nutr 2004;24:151-72.
38. Andrews GK. Regulation of metallothionein gene expression by oxidative stress and metal ions. Biochem Pharmacol 2000;59:95-104.
39. Langmade SJ, Ravindra R, Daniels PJ, Andrews GK. The transcription factor MTF-1 mediates metal regulation of the mouse ZnT1 gene. J Biol Chem 2000;275:34803-9.
40. Jacob C, Maret W, Vallee BL. Control of zinc transfer between thionein, metallothionei n, and zinc proteins. Proc Natl Acad Sci U S A 1998;95:3489-94.
41. Bittel D, Dalton T, Samson SL, Gedamu L, Andrews GK. The DNA binding activity of metal response element-binding transcription factor-1 is activated in vivo and in vitro by zinc, but not by other transition metals. J Biol Chem 1998;273:7127-33.
42. Saydam N, Steiner F, Georgiev O, Schaffner W. Heat and heavy metal stress synergize to mediate transcriptional hyperactivation by metal-responsive transcription factor MTF-1. J Biol Chem 2003;278:31879-83.
43. Lichtlen P, Schaffner W. The "metal transcription factor" MTF-1: biological facts and medical implications. Swiss Med Wkly 2001; 131: 647-52.
44. Joseph TJ, Wereley JP, Chitambar CR. Gallium nitrate as a novel agent for the treatment of mantle cell lymphoma: targets and mechanisms of action. Proc Am Assoc Cancer Res 2005;46:1383-4.
45. Huang Z, Higgins B, Foss F. Activity of gallium nitrate in refractory peripheral T-cell lymphoma. Clin Lymphoma 2005;6:43-5.